Neurotone AI

Cover Block

PUBLIC

Name	Neurotone AI
Tagline	AI-powered auditory rehabilitation platforms for hearing professionals
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Founding Team	Rick Carlson, Miles Aaron
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.neurotone.com/
• LinkedIn: https://www.linkedin.com/company/neurotoneai

Executive Summary

PUBLIC

Neurotone AI is building a specialized, evidence-based software wedge into the hearing care professional channel, a market where digital adoption remains low but clinical outcomes are paramount. The company's focus on auditory rehabilitation for hearing loss and tinnitus, sold through lifetime licenses to clinics, represents a capital-efficient, high-margin SaaS model targeting a niche but sticky B2B customer base [Perplexity Sonar, 2024]. Its recent launch of Tinnitus Pro in October 2024 combines sound therapy, cognitive behavioral tools, and clinician monitoring into a single platform, aiming to address a chronic condition with limited effective treatment options [PRWeb, Oct 2024].

The company's foundational product, LACE, and its AI-enhanced successor, Lace AI Pro, are supported by a substantial body of clinical research, a critical differentiator in a healthcare-adjacent field [The Audiology Place, 2026]. Co-founders Rick Carlson (CEO) and Dr. Miles Aaron (COO) lead the firm, with Carlson's tenure beginning in March 2022 [Clay.earth / LinkedIn, 2026]. The product development of Tinnitus Pro involved recognized clinical advisors, including Dr. Robert Sweetow and Dr. Nancy Tye-Murray, lending credibility to its therapeutic approach [The Hearing Review, 2024].

Funding details are not publicly disclosed, though investor names like Charlotte Angel Fund and Temprano Techvestors are listed in databases [Crunchbase, 2024]. The business model centers on one-time or clinic-wide license sales to hearing professionals, a departure from recurring patient subscriptions, which may accelerate initial adoption but raises questions about long-term revenue visibility [Perplexity Sonar, 2024]. Over the next 12-18 months, the key watchpoints will be the commercial uptake of Tinnitus Pro following its launch, any shift toward a recurring revenue model, and the company's ability to translate its clinical validation into scalable enterprise sales.

Data Accuracy: YELLOW -- Core product and launch details are cited from trade press and company support pages, but key financial and operational metrics remain unconfirmed.

Taxonomy Snapshot

Axis	Value
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning

Company Overview

PUBLIC

Neurotone AI operates as a specialized software provider in the audiology space, with its public identity built around the acquisition and modernization of a long-standing clinical tool. The company's primary asset appears to be the LACE (Listening and Communication Enhancement) auditory training program, a product with a clinical history predating the current entity [The Audiology Place, 2026]. Neurotone AI's recent corporate activity centers on integrating AI into this established platform and expanding into adjacent therapeutic areas, most notably with the launch of a digital tinnitus treatment product [PRWeb, Oct 2024].

Key leadership includes CEO and co-founder Rick Carlson, who has been in that role since at least March 2022, and co-founder and COO Dr. Miles Aaron [Clay.earth / LinkedIn, 2026] [Hearing Health & Technology Matters, 2025]. The company has also established affiliations with prominent clinical advisors, including Dr. Nancy Tye-Murray, PhD, and collaborated with specialists like Dr. Robert Sweetow and Dr. Jennifer Henderson Sabes on product development [The Hearing Review, 2024] [LinkedIn, 2026]. A significant reported milestone is the company's acquisition of Amptify, another digital auditory training platform, in 2026, suggesting a strategy of consolidation within the niche [The Hearing Review, 2026].

Operational details are sparse. The company's headquarters location is not publicly listed, and its founding date is unconfirmed. Public milestones are primarily product-focused: the launch of Tinnitus Pro in October 2024 and the rebranding of its core offering to Lace AI Pro following a partnership with the program's original creators in early 2024 [PRWeb, Oct 2024] [Neurotone support, 2024]. The business model targets hearing care professionals directly, selling lifetime software licenses rather than recurring SaaS subscriptions, which indicates a specific approach to monetization in a traditionally slow-to-adopt vertical [Perplexity Sonar, 2024].

Data Accuracy: YELLOW -- Key executive roles and product launches are cited in trade press, but foundational corporate details (founding date, HQ) lack independent corroboration.

Product and Technology

MIXED

Neurotone AI's product strategy centers on a suite of B2B software platforms designed to serve hearing care professionals, not end consumers directly. The company's wedge is a clinical one, offering tools that aim to improve patient outcomes through personalized auditory training and therapy, thereby addressing downstream business problems like hearing aid returns and patient retention for audiologists. The product line appears to be built on a legacy of clinical validation, with its core LACE technology supported by more than 80 peer-reviewed publications and over 10 clinical trials [The Audiology Place, 2026].

Two primary products have been publicly launched. The first is Lace AI Pro, an evolution of the established LACE (Listening and Communication Enhancement) auditory training software. According to the company, this version was developed in early 2024 through a collaboration with the program's original creators to "significantly advance AI technology" [Neurotone support, 2024]. The platform is designed to improve auditory comprehension, particularly in challenging listening environments. The second, and more recent, launch is Tinnitus Pro, announced in October 2024 [PRWeb, Oct 2024]. This product integrates sound therapy, cognitive behavioral therapy (CBT) tools, and clinician monitoring into a single digital application for tinnitus management. Both products are sold via lifetime licenses to hearing professionals, with Tinnitus Pro cited at a $499 price point for patient licenses, alongside clinic pricing options [Perplexity Sonar, 2024].

A key aspect of the technology is its intended integration into a clinician's workflow. The platforms include clinician portals for assigning exercises, monitoring patient progress, and adjusting therapy plans. This design suggests a focus on creating a sticky, practice-level software tool rather than a direct-to-consumer wellness app. The company's recent acquisition of Amptify, another digital auditory training platform, points to a consolidation strategy within this niche [The Hearing Review, 2026]. While specific details on the AI stack are not disclosed, the application of machine learning is inferred to be focused on personalizing therapy regimens and exercise difficulty based on individual patient performance data.

Data Accuracy: YELLOW -- Product details and pricing are sourced from company support pages and a single press release; the clinical research backing for LACE is well-documented in trade publications.

Market Research

PUBLIC

The market for digital auditory rehabilitation tools is being reshaped by a convergence of demographic pressure, clinical evidence, and a shift toward value-based hearing care, creating a clear opening for software that improves patient adherence and outcomes.

Quantitative market sizing for this specific niche is not directly cited in public sources for Neurotone AI. However, the broader context is defined by the aging global population and the high prevalence of hearing loss. According to the World Health Organization, over 1.5 billion people worldwide live with some degree of hearing loss, a figure projected to rise to nearly 2.5 billion by 2050 [WHO, 2021]. Within this population, tinnitus is a common comorbidity, affecting an estimated 10-15% of adults. The core customer segment for Neurotone's B2B software,licensed hearing care professionals,operates within the larger hearing aid market, which was valued at approximately $10.5 billion globally in 2023 and is forecast to grow at a compound annual rate of roughly 6% [Fortune Business Insights, 2024]. This serves as an analogous market for the addressable service provider base.

Demand is driven by several persistent tailwinds. The clinical adoption of remote patient monitoring and telehealth tools, accelerated during the pandemic, has created a more receptive environment for digital therapeutic adjuncts. Furthermore, hearing aid adoption in the U.S. received a structural boost from the 2022 FDA rule establishing a new over-the-counter category, which is expected to increase overall market awareness and downstream demand for supporting rehabilitation services. A critical driver for professional-grade tools is the economic incentive to reduce hearing aid returns, which industry analyses often cite as a significant cost center for clinics; software that demonstrably improves patient adaptation and satisfaction directly addresses this pain point.

Key adjacent markets include the broader digital therapeutics sector for neurological conditions and the consumer-facing cognitive training app market. Regulatory forces are generally favorable but nuanced. In the U.S., while the software may be classified as a low-risk digital health tool, claims related to tinnitus treatment or auditory training could attract scrutiny from the FDA if positioned as a medical device. The company's strategy of selling directly to clinicians, rather than as a direct-to-consumer product, likely simplifies the regulatory pathway. Macro forces, particularly the focus on value-based care in audiology, incentivize providers to adopt tools that deliver measurable, long-term patient outcomes rather than just selling hardware.

Metric	Value
Global Hearing Aid Market 2023	10.5 $B
Projected CAGR 2024-2030	6 %
People with hearing loss 2023	1.5 Billion
Projected with hearing loss 2050	2.5 Billion

The chart illustrates the substantial and growing underlying population for hearing services, which forms the foundation of demand for clinical tools like those Neurotone AI provides. The steady growth of the hearing aid market suggests a stable, non-cyclical customer base for adjacent software solutions.

Data Accuracy: YELLOW -- Market sizing figures are from third-party global health and industry reports, not company-specific estimates. The application to Neurotone's specific SAM is inferred.

Competitive Landscape

MIXED, Neurotone AI operates in a niche where competition is defined less by direct feature-for-feature rivals and more by a fragmented ecosystem of point solutions, adjacent services, and the status quo of manual clinical practice.

Without a named competitor in the structured facts, a direct comparison table is not possible. The competitive analysis must therefore be reconstructed from the company's stated product focus and the known contours of the auditory rehabilitation market.

The competitive map segments into three layers. First, incumbent software tools like the original LACE program, which Neurotone AI's Lace AI Pro succeeds, represent legacy products that are being actively upgraded. Second, adjacent digital health substitutes include broad-based cognitive training apps (e.g., Lumosity), meditation apps with soundscapes (e.g., Headspace for tinnitus), and direct-to-consumer hearing aid companion apps from manufacturers like Phonak or Widex. These compete for patient attention and engagement rather than for the clinician's dollar. Third, and most significant, is the manual standard of care: the in-clinic counseling and paper-based exercises that many audiologists still use, which constitute the primary alternative to any digital tool.

Neurotone AI's defensible edge appears to rest on two pillars. The first is proprietary clinical evidence. The claim that the LACE methodology is supported by over 80 peer-reviewed publications and 10+ clinical trials [The Audiology Place, 2026] creates a barrier to entry that generic wellness apps cannot easily overcome. This evidence is bundled into their clinician-facing sales pitch. The second is the integrated clinician portal. By selling lifetime licenses to hearing care professionals [Perplexity Sonar, 2024] and providing tools for monitoring patient progress, the company embeds itself into the clinical workflow. This B2B2C model is less exposed to the volatility of direct-to-consumer subscription churn.

This edge is durable only if the company continues to invest in clinical validation for its new products, like Tinnitus Pro, and maintains its focus on the professional channel. It is perishable if larger hearing aid manufacturers decide to build or buy similar integrated software suites, leveraging their existing deep clinician relationships.

The company's most significant exposure is its narrow commercial footprint. It does not own the patient relationship directly, relying on clinicians to prescribe its tools. It also does not own the hearing aid hardware, where major manufacturers could potentially bundle competitive software for free. A specific threat would be a company like Cochlear or Demant acquiring a competing software startup and making it an exclusive part of their fitting software, locking Neurotone out of a large segment of clinics.

The most plausible 18-month scenario involves continued niche consolidation. A "winner" in this segment will be the company that successfully bundles multiple auditory rehabilitation modules (listening in noise, tinnitus, auditory processing) into a single, clinician-preferred platform. Neurotone AI, with its launches of Lace AI Pro and Tinnitus Pro [PRWeb, Oct 2024], is attempting this. A "loser" would be a standalone, single-condition digital therapeutic app that fails to demonstrate measurable reductions in hearing aid returns or improvements in patient satisfaction, causing clinicians to abandon it for more comprehensive solutions.

Data Accuracy: YELLOW, Competitive positioning is inferred from product claims and market structure; no direct competitor data is publicly available for corroboration.

Opportunity

PUBLIC

The prize for Neurotone AI is the transformation of the hearing care clinic from a hardware-centric sales channel into a high-retention, high-margin software-enabled service hub, capturing recurring value from the estimated 1.5 billion people globally with hearing loss [WHO, 2023].

The headline opportunity is to become the default clinical operating system for auditory rehabilitation. The company's bet is that hearing aids, while necessary, are insufficient for patient outcomes and clinic economics. By embedding its AI-driven training and therapy software into the clinician's workflow, Neurotone AI aims to create a new, sticky revenue layer on top of the existing hardware sale. The evidence that this outcome is reachable, not merely aspirational, lies in the clinical validation of its core technology. The LACE program, the predecessor to Lace AI Pro, is supported by more than 80 peer-reviewed publications and over 10 clinical trials [The Audiology Place, 2026]. This depth of scientific backing provides a defensible wedge into a conservative, evidence-driven medical field, making adoption by hearing professionals a plausible first step toward systemic integration.

Growth scenarios for scaling beyond a niche software vendor are tied to specific product and partnership catalysts. The table below outlines two concrete paths.

Scenario	What happens	Catalyst	Why it's plausible
Integrated Care Platform	Neurotone AI's software becomes a bundled, non-negotiable component of major hearing aid manufacturers' fitting protocols.	A white-label or OEM partnership with a top-5 hearing aid manufacturer (e.g., Sonova, Demant, WS Audiology).	The company's recent launch of Tinnitus Pro demonstrates an ability to develop and integrate new, complementary therapy modules [PRWeb, Oct 2024]. Manufacturers are seeking software differentiation to reduce return rates and improve patient satisfaction, creating a clear partnership incentive.
Direct-to-Consumer Pivot	The company leverages its clinical brand to launch a supervised, direct-to-patient subscription service, bypassing the clinic for a segment of the market.	The launch of a patient-facing app tier, marketed as "clinician-recommended" but available via direct download.	The lifetime license model sold to professionals [Perplexity Sonar, 2024] establishes a trusted brand with clinicians, whose referrals could legitimize a direct-to-consumer offering. The acquisition of Amptify, a direct-to-consumer auditory training app, in 2026 provides the technology and experience for this channel [The Hearing Review, 2026].

What compounding looks like is a classic data and distribution flywheel. Each new clinic deployment generates more patient interaction data, which is used to refine the personalization algorithms within Lace AI Pro and Tinnitus Pro. More effective algorithms lead to better published clinical outcomes, which in turn attract more clinics and strengthen the company's value proposition to potential manufacturing partners. This creates a distribution lock-in: as protocols are built around Neurotone's tools, switching costs for clinics rise. The flywheel's first turn is evidenced by the expansion from LACE to Lace AI Pro and then to the integrated Tinnitus Pro module, showing a product development cadence that leverages a common platform and clinical audience [Neurotone support, 2024] [The Hearing Review, 2024].

The size of the win can be framed by looking at a comparable. Cochlear Limited, a pure-play hearing implant company, maintains a market capitalization of approximately $15 billion. While Neurotone AI does not manufacture hardware, its opportunity is to capture the high-margin, recurring software and service revenue attached to the broader hearing health ecosystem. If the Integrated Care Platform scenario plays out, capturing even a single-digit percentage of the service revenue attached to the tens of millions of hearing aids sold annually could support a valuation in the hundreds of millions. A more direct comparable might be the 2021 acquisition of hearing test app maker Hearing Tracker by hearing aid retailer hear.com for an undisclosed sum, signaling strategic value in owning patient-facing auditory health software. A successful execution of either growth scenario positions Neurotone AI as a strategic asset, either for a hearing aid manufacturer or a larger digital health platform seeking audiology depth.

Data Accuracy: YELLOW -- Core product claims and team affiliations are cited from trade press and company materials, but key commercial metrics (customer count, revenue) and partnership details are not publicly available.

Sources

PUBLIC

1. [Perplexity Sonar, 2024] Neurotone AI Brief | https://www.perplexity.ai/

2. [PRWeb, Oct 2024] Neurotone AI Launches Tinnitus Pro: The Next Revolution in Tinnitus Treatment | https://www.prweb.com/releases/neurotone-ai-launches-tinnitus-pro-the-next-revolution-in-tinnitus-treatment-302616530.html

3. [The Audiology Place, 2026] LACE AI Pro Explained | https://theaudiologyplace.com/lace-ai-pro-explained

4. [Clay.earth / LinkedIn, 2026] Rick Carlson Profile | https://clay.earth/rickcarlson

5. [Hearing Health & Technology Matters, 2025] Neurotone AI Profile | https://hearinghealthmatters.org/technology/neurotone-ai/

6. [The Hearing Review, 2024] Neurotone AI Launches Tinnitus Pro | https://hearingreview.com/hearing-loss/tinnitus/tinnitus-therapy/neurotone-ai-launches-tinnitus-pro

7. [LinkedIn, 2026] Nancy Tye-Murray Profile | https://www.linkedin.com/in/nancy-tye-murray-phd-57664035/

8. [Neurotone support, 2024] What is Lace AI Pro? Who is Neurotone AI? | https://support.neurotone.com/what-is-lace-ai-pro-who-is-neurotone-ai

9. [Crunchbase, 2024] Neurotone AI - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/neurotone-ai

10. [The Hearing Review, 2026] Neurotone AI Acquires Amptify to Advance Auditory Training | https://hearingreview.com/inside-hearing/organizations/neurotone-ai-acquires-amptify-to-advance-auditory-training

11. [WHO, 2021] World report on hearing | https://www.who.int/publications/i/item/world-report-on-hearing

12. [Fortune Business Insights, 2024] Hearing Aids Market Size & Share | https://www.fortunebusinessinsights.com/hearing-aids-market-102065

13. [WHO, 2023] Deafness and hearing loss | https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss